• NBC19: Nanomolar NLRP3 Inflammasome Inhibitor for Research

  2026-05-30

  NBC19 is a potent NLRP3 inflammasome inhibitor with sub-100 nM efficacy in suppressing IL-1β release in THP1 cells. Its benchmarked potency and specificity make it valuable for modeling inflammatory signaling and studying disease mechanisms. This article details its mechanism, evidence base, and practical workflow parameters.

• Pomalidomide (CC-4047): Data-Driven Solutions for Myeloma Re

  2026-05-29

  This article delivers scenario-driven, evidence-based guidance on deploying Pomalidomide (CC-4047) (SKU A4212) for reliable cell viability, proliferation, and cytotoxicity assays in hematological malignancy research. Drawing on quantitative data and best practices, it addresses real-world experimental challenges and highlights APExBIO’s product advantages for reproducible results.

• Metronidazole: Mechanism, OAT3 Inhibition, and Research Util

  2026-05-29

  Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol) is a nitroimidazole antibiotic and potent OAT3 inhibitor. It demonstrates robust inhibition of human organic anion transporters and is widely used for anaerobic bacteria targeting and protozoa research. Its defined transport inhibition profile and solubility make it a strategic reagent for pharmacology and translational studies.

• VX-745: Precision p38α MAPK Inhibitor Workflows & Solutions

  2026-05-28

  VX-745 stands out as a highly selective p38α MAPK inhibitor, enabling researchers to dissect inflammatory and oncogenic signaling with unprecedented clarity. This guide details optimized experimental workflows, troubleshooting strategies, and the dual-action mechanistic edge VX-745 brings to advanced disease models.

• Dimethyloxalylglycine (DMOG): Protocols for Hypoxia Modeling

  2026-05-28

  Dimethyloxalylglycine (DMOG) enables researchers to stabilize hypoxia-inducible factors and replicate hypoxic signaling in vitro and in vivo, supporting precise studies of oxygen sensing, inflammation, and infection models. It is not intended for diagnostic or clinical use, and reliable results require strict adherence to solubility and storage guidelines.

• SGI-1027 and Everolimus Synergy in Renal Cancer via Lysosoma

  2026-05-27

  This study reveals that the DNMT1 inhibitor SGI-1027, in combination with the mTOR inhibitor everolimus, synergistically induces both apoptosis and GSDME-dependent pyroptosis in renal cell carcinoma by promoting lysosomal membrane permeability. These findings provide an innovative strategy for overcoming everolimus resistance in advanced RCC, with implications for multi-modal cell death targeting.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-05-27

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase (TrxR) and MAPK pathways to enhance antitumor immune responses. By modulating both tumor immunogenicity and the immunosuppressive microenvironment in liver cancer, 6d demonstrates a multidimensional mechanism for improving immunotherapy outcomes.

• EZ Cap™ Firefly Luciferase mRNA: Optimized Reporter Workflow

  2026-05-26

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure delivers robust, reproducible gene regulation and bioluminescent imaging, outperforming conventional mRNA reporters in both stability and translational efficiency. Its synergy with lipid nanoparticle systems and precise protocol parameters empower advanced molecular biology and in vivo research.

• Triptolide (PG490): Precision Tool for Cancer Research Workf

  2026-05-26

  Triptolide (PG490) delivers nanomolar-range transcriptional inhibition and apoptosis induction, unlocking advanced capabilities in cancer and immunology research. This article provides actionable workflows, troubleshooting strategies, and evidence-backed insights, leveraging APExBIO’s reliable sourcing for reproducibility and clarity.

• Pomalidomide (CC-4047) Workflows in Hematological Malignancy

  2026-05-25

  Explore how Pomalidomide (CC-4047) empowers researchers to dissect the complexity of multiple myeloma and other hematological malignancies by precisely targeting the tumor microenvironment and cytokine networks. This deep-dive details protocol enhancements, troubleshooting tips, and actionable insights drawn from the latest mutational landscape studies.

• Isoprinosine (Inosine Pranobex): Mechanism, Evidence, and Pr

  2026-05-25

  Isoprinosine, also known as inosine pranobex, is a clinically validated immunomodulatory agent and direct inhibitor of herpesvirus replication. Its dual action—immune enhancement and viral egress inhibition—makes it a benchmark compound for acute respiratory viral infection research. Evidence supports its safety and efficacy in specific patient populations, with fewer side effects than many conventional antivirals.

• Pam3CSK4 TFA: Precision TLR1/2 Agonist for Innate Immunity W

  2026-05-24

  Pam3CSK4 TFA enables precise and reproducible TLR1/2 pathway activation, powering advanced cytokine profiling in maternal-neonatal immunity and translational inflammation research. This guide demystifies experimental design, highlights key protocol variables, and delivers actionable troubleshooting for maximizing data quality with this high-purity TLR1/2 agonist.

• Recombinant Human IL-15: Advancing Neuroimmune Research Prec

  2026-05-23

  Explore how Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) enables groundbreaking neuroimmune research by providing unmatched purity and activity for precise T and NK cell modulation. This article uniquely bridges high-fidelity immune assays with novel insights from early life adversity models.

• Losartan and AT1R Endocytosis: New Frontiers in Hypertension

  2026-05-22

  Explore how Losartan, a selective angiotensin II receptor antagonist, reveals novel mechanisms in cardiovascular and renal research by modulating AT1 receptor internalization. Gain advanced insights for assay design and therapeutic discovery beyond standard hypertension models.

• Nerve-Dependent HDAC1 Regulation Drives Axolotl Limb Regener

  2026-05-22

  This study elucidates how nerve-mediated upregulation of HDAC1 is essential for blastema formation and successful limb regeneration in axolotls. By employing selective HDAC inhibitors such as MS-275 (Entinostat), the authors demonstrate the epigenetic mechanisms linking nerve signaling to regenerative outcomes, offering insights for both developmental biology and translational research.

16268 records 1/1085 page Next 12345 下5页 Last page